These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 10838448)

  • 21. Rituximab for the treatment of high titre inhibitors in mild haemophilia A.
    Dolničar MB; Rajić V; Kitanovski L; Debeljak M
    Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s345-7. PubMed ID: 23522890
    [No Abstract]   [Full Text] [Related]  

  • 22. Inhibitors in haemophilia: clinical aspects.
    Dimichele D; Rivard G; Hay C; Antunes S
    Haemophilia; 2004 Oct; 10 Suppl 4():140-5. PubMed ID: 15479387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The treatment of factor VIII inhibitors--a general overview.
    White GC; Roberts HR
    Vox Sang; 1996; 70 Suppl 1():19-23. PubMed ID: 8869464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant use of epsilon-aminocaproic acid (Amicar) in the endovascular treatment of cranial arteriovenous fistulae.
    Kallmes DF; Marx WF; Jensen ME; Cloft HJ; Do HM; Lanzino G; West K; Dion JE
    Neuroradiology; 2000 Apr; 42(4):302-8. PubMed ID: 10872177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of epsilon aminocaproic acid and tranexamic Acid in thoracic aortic surgery: clinical efficacy and safety.
    Makhija N; Sarupria A; Kumar Choudhary S; Das S; Lakshmy R; Kiran U
    J Cardiothorac Vasc Anesth; 2013 Dec; 27(6):1201-7. PubMed ID: 24050855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of epsilon-aminocaproic acid during peritoneal dialysis.
    Fish SS; Pancorbo S; Berkseth R
    J Neurosurg; 1981 Jun; 54(6):736-9. PubMed ID: 7241183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune response against serial infusion of factor VIII antigen through an implantable venous-access device system in haemophilia A mice.
    Madoiwa S; Kobayashi E; Kashiwakura Y; Sakata A; Yasumoto A; Ohmori T; Mimuro J; Sakata Y
    Haemophilia; 2012 May; 18(3):e323-30. PubMed ID: 22044430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Second-generation recombinant factor VIII and inhibitor risk: interpretation of RODIN study findings and implications for patients with haemophilia A.
    van der Bom JG; Gouw SC; Rosendaal FR
    Haemophilia; 2014 Mar; 20(2):e171-4. PubMed ID: 24372628
    [No Abstract]   [Full Text] [Related]  

  • 29. Switching haemophilia products and inhibitor risk: a United States' perspective.
    Nance D; Rodgers GM
    Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
    [No Abstract]   [Full Text] [Related]  

  • 30. High-titre factor VIII inhibitor in two children with mild haemophilia A.
    Puetz JJ; Bouhasin JD
    Haemophilia; 2001 Mar; 7(2):215-9. PubMed ID: 11260282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitors of factor VIII: detection and treatment.
    Brettler DB
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():21-5. PubMed ID: 7886576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cross-reactivity to porcine factor VIII of factor VIII inhibitors in patients with haemophilia in Australia and New Zealand.
    Lloyd JV; Street AM; Berry E; McPherson J; Ekert H; Lammi A; McWhirter WR; Duncan EM; Maxwell EL; Rowell J; Baker RI; Leahy MF; Jupe D
    Aust N Z J Med; 1997 Dec; 27(6):658-64. PubMed ID: 9483232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recommendations for the treatment of factor VIII inhibitors: from the UK Haemophilia Centre Directors' Organisation Inhibitor Working Party.
    Hay CR; Colvin BT; Ludlam CA; Hill FG; Preston FE
    Blood Coagul Fibrinolysis; 1996 Mar; 7(2):134-8. PubMed ID: 8735802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased recombinant activated factor VII use and need for surgical reexploration following a switch from aprotinin to epsilon-aminocaproic acid in infant cardiac surgery.
    Scott JP; Costigan DJ; Hoffman GM; Simpson PM; Dasgupta M; Punzalan R; Berens RJ; Tweddell JS; Stuth EA
    J Clin Anesth; 2014 May; 26(3):204-11. PubMed ID: 24809789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay.
    Turecek PL; Váradi K; Keil B; Negrier C; Berntorp E; Astermark J; Bordet JC; Morfini M; Linari S; Schwarz HP
    Pathophysiol Haemost Thromb; 2003; 33(1):16-22. PubMed ID: 12853708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitors to factor VIII in a family with mild hemophilia: molecular characterization and response to factor VIII and desmopressin.
    Santagostino E; Gringeri A; Tagliavacca L; Mannucci PM
    Thromb Haemost; 1995 Aug; 74(2):619-21. PubMed ID: 8584995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitor to factor VIII in mild haemophilia.
    Kesteven PJ; Holland LJ; Lawrie AS; Savidge GF
    Thromb Haemost; 1984 Aug; 52(1):50-2. PubMed ID: 6437010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival of transfused factor VIII in hemophilic patients treated with epsilon aminocaproic acid.
    Weiss AE; Webster WP; Strike LE; Brinkhous KM
    Transfusion; 1976; 16(3):209-14. PubMed ID: 936268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of tranexamic acid and ε-aminocaproic acid concentrations required to inhibit fibrinolysis in plasma of dogs and humans.
    Fletcher DJ; Blackstock KJ; Epstein K; Brainard BM
    Am J Vet Res; 2014 Aug; 75(8):731-8. PubMed ID: 25061704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PHARMACOKINETIC STUDY OF ORAL ε-AMINOCAPROIC ACID IN THE NORTHERN ELEPHANT SEAL (MIROUNGA ANGUSTIROSTRIS).
    Kaye S; Johnson S; Arnold RD; Nie B; Davis JT; Gulland F; Abou-Madi N; Fletcher DJ
    J Zoo Wildl Med; 2016 Jun; 47(2):438-46. PubMed ID: 27468014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.